Advertisement
| anti her2 antibody therapy: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| anti her2 antibody therapy: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| anti her2 antibody therapy: Safety of Biologics Therapy Brian A. Baldo, 2016-08-12 This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences. |
| anti her2 antibody therapy: Introduction to Biological and Small Molecule Drug Research and Development C. Robin Ganellin, Roy Jefferis, Stanley M. Roberts, 2013-05-07 Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the book is actually put into practice. Studies include Herceptin/T-DM1, erythropoietin (Epogen/Eprex/NeoRecormon), anti-HIV protease inhibitor Darunavir, and more. Introduction to Biological and Small Molecule Drug Research and Development is intended for late-stage undergraduates or postgraduates studying chemistry (at the biology interface), biochemistry, medicine, pharmacy, medicine, or allied subjects. The book is also useful in a wide variety of science degree courses, in post-graduate taught material (Masters and PhD), and as basic background reading for scientists in the pharmaceutical industry. - For the first time, the fundamental scientific principles of biopharmaceuticals and small molecule chemotherapeutics are discussed side-by-side at a basic level - Edited by three senior scientists with over 100 years of experience in drug research who have compiled the best scientific comparison of small molecule and biopharmaceuticals approaches to new drugs - Illustrated with key examples of important drugs that exemplify the basic principles of pharmaceutical drug research and development |
| anti her2 antibody therapy: Advances in Breast Cancer Management, 2nd edition William J. Gradishar, William C. Wood, 2000-08-31 The optimal management of breast cancer patients relies on the expertise of a team of medical specialists including radiologists, surgeons, radiation therapists and medical oncologists. Much of the progress in breast cancer management made over the last several years reflects the translation of observations made in the laboratory to the clinic. Critically evaluating the impact of new treatment approaches relies on a commitment to well-designed clinical trials. In this volume, Advances in Breast Cancer Management, a renowned group of breast cancer experts have been asked to provide their perspective on management issues that directly effect patients on a day-to-day basis. Dr. Melody Cobleigh discusses the consequences of estrogen deprivation and the ways of ameliorating secondary symptoms and the potential long-term morbidity. Drs. Haigh and Guiliano review the sentinel lymph node biopsy technique including results from their extensive experience. Dr. Abram Recht places into perspective the potential benefit of post-mastectomy radiotherapy and reviews recent trials that address this issue. Dr. Dennis Slamon takes from us from the laboratory to the clinic in explaining the development of Herceptin as a paradigm for therapy targeted to specific molecular characteristics of breast cancer tumor cells. Drs. Nieto, Shpall, Crump and Pritchard offer different perspectives on the future of high-dose chemotherapy with stem cell transplantation as a treatment for breast cancer patients. Drs. |
| anti her2 antibody therapy: Handbook of Therapeutic Antibodies Stefan Dübel, Janice M. Reichert, 2014-12-03 Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle. |
| anti her2 antibody therapy: Antibody Engineering Patrick Chames, 2016-08-23 More than ever, antibodies are being recognized as a major drug modality in a variety of diseases, including cancer, autoimmune diseases, infectious diseases, or even neurodegenerative disorders. Over 30 therapeutic antibodies have been approved and novel molecules are entering clinical trials at an average rate of 50 per year and that is predicted to continue well into the future. Notwithstanding the many achievements already made in the field, there is still a lot of room for improvements for these molecules in terms of activity, and a plethora of approaches have been attempted to optimize these molecules. Antibody Engineering: Methods and Protocols, Second Edition was compiled to give complete and easy access to a variety of antibody engineering techniques, starting from the creation of antibody repertoires and efficient ways to select binders from these repertoires, to their production in various hosts, their detailed characterization using various well established techniques, and to the modification and optimization of these lead molecules in terms of binding activity, specificity, size, shape, and more. Written in the successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Antibody Engineering: Methods and Protocols, Second Edition serves as an invaluable resource for both experts and those new to the field, and most of all as a source of inspiration for the creation of the antibodies of tomorrow. |
| anti her2 antibody therapy: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| anti her2 antibody therapy: Her-2 Robert Bazell, 2011-04-27 Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a compassionate use program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. |
| anti her2 antibody therapy: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| anti her2 antibody therapy: Innovations for Next-Generation Antibody-Drug Conjugates Marc Damelin, 2018-05-29 Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients. |
| anti her2 antibody therapy: Translational Research in Breast Cancer Dong-Young Noh, Wonshik Han, Masakazu Toi, 2021-05-13 This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to the bench for basic research, as well as findings that have been applied back to the bedside. Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer. |
| anti her2 antibody therapy: Monoclonal Antibody Therapy of Human Cancer Kenneth A. Foon, Alton C. Morgan, 1985-09-30 KENNETH A. FOON and ALTON C. MORGAN, JR. Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed. These studies have generally been attempted in patients with large tumor burdens, and as would be expected, results have been transient at best. A wide variety of solid tumors as well as leukemias and lym phomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sick ness, and severe cytopenias have been encountered with these antisera. There are a number of potential mechanisms by which unconju gated antibodies might be cytotoxic to tumor cells. Antibodies bound to the cell surface membrane of tumor cells may lead to cell lysis by complement-dependent or antibody-dependent cellu lar cytotoxicity. Circulating tumor cells bound by antibody may be more susceptible to phagocytosis by the reticuloendothelial system. Antibody bound to the cell surface membrane of tumor cells may enhance immunogenicity of the tumor cell leading to activation of the host's immune system. |
| anti her2 antibody therapy: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| anti her2 antibody therapy: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry Stephanie K. Ashenden, 2021-04-23 The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics. - Demonstrates how the prediction of toxic effects is performed, how to reduce costs in testing compounds, and its use in animal research - Written by the industrial teams who are conducting the work, showcasing how the technology has improved and where it should be further improved - Targets materials for a better understanding of techniques from different disciplines, thus creating a complete guide |
| anti her2 antibody therapy: Management of Cancer in the Older Patient E-Book Arash Naeim, David Reuben, Patricia Ganz, 2011-08-17 Management of Cancer in the Older Patient, by Drs. Arash Naeim, David Reuben, and Patricia Ganz, offers the help you need to effectively diagnose, refer, and manage cancer in geriatric patients. You’ll see how to provide effective cancer screening; refer your patients to the right oncologist; deal with comorbidities, frailties, and other complications; navigate end-of-life issues; and much more. A templated, user-friendly format makes it easy to find and apply the answers you need. See how to best manage geriatric cancer patients with help from leading specialists in both geriatrics and oncology Make informed decisions as to when to refer patients to specialists. Provide the supportive care your patients and their families need on issues such as such as mental health, pain, fatigue, nausea, insomnia. Be prepared to help cancer survivors navigate their after-treatment care including adjuvant therapy, side effects, second cancers, quality of life, and other concerns. Offer accurate guidance on ethical issues like competency, end of life, hospice, the role of the caregiver, and more. |
| anti her2 antibody therapy: Introduction to Cancer Metastasis Aamir Ahmad, 2016-11-14 Introduction to Cancer Metastasis provides, in one place, an overview of organ-specific cancer metastasis and the most common sites of cancer metastasis. Through specific chapters on individual primary cancers, their metastasis, and chapters on common metastatic sites, this volume comprehensively informs readers about the broader knowledge base in cancer metastasis. The process of metastasis is particularly responsible for making cancer so lethal. This volume explores both metastasis from sites of origin and common metastatic sites, thus increasing understanding of both perspectives. - Includes basic biology and translational approaches to organ-specific cancer sites - Provides readers with information on emerging therapeutic targets for cancer metastasis - Contains contributions from leading researchers around the globe |
| anti her2 antibody therapy: Cytotoxic Payloads for Antibody–Drug Conjugates David E Thurston, Paul J M Jackson, 2019-07-11 Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future. |
| anti her2 antibody therapy: Cardio-Oncology Roberta A. Gottlieb, Puja K Mehta, 2016-11-26 Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well as for cardio-oncology researchers. - Covers basic science of cardio-oncology to provide readers with the necessary background - Addresses cardiotoxicity related to current cancer therapeutic modalities - Discusses diagnostic and management approaches of patients with underlying cardiac risk factors as well as otherwise healthy cancer patients |
| anti her2 antibody therapy: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins Ulf Grawunder, Stefan Barth, 2017-04-07 This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology. |
| anti her2 antibody therapy: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| anti her2 antibody therapy: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| anti her2 antibody therapy: Cancer and Autoimmunity M.E. Gershwin, Yehuda Shoenfeld, 2000-03-27 Of the two disciplines in parallel development for two decades, tumor immunology and transplantation immunology, the latter has thrived and has led to some of the most critical discoveries in immunobiology. The former continues to thwart both scientists and clinicians alike.The goal of immunologists in modern day research is to develop a simple and effective means to manipulate cancer in vivo, possibly encompassing several venues: identifying a phenotypic marker and the use of either active or passive immunization; include the use of passive reagents carrying warheads to selectively destroy cancer cells; or altering the basic process of cell survival.This excellent multidiscipline-authored volume presents a theme which has not been well described before. The papers include both basic and clinical science and range from sophisticated molecular biology to little more than phenomenology (e.g. the increased association of cancer in some autoimmune diseases and increased presentation of autoimmune phenomena in malignant condition). This, however, is state-of-the-art.This collection of themes will be of use not only to bench scientists, but also to clinicians who treat patients. The book represents progress at the cutting edge of this discipline, and points the way to further developments in the black box of immunology. |
| anti her2 antibody therapy: Encyclopedia of Pathology , 2016-07-14 The scope of this 15-20-volume set encompasses the entire field of pathology ranging from general pathological terms to specific diseases to diagnostic methods. Each volume contains homogenously structured entries and a team of international experts guarantee that the essays and definitions are scientifically sound. The A-Z format allows searching for a single word in case the reader does not know to which pathological speciality the term belongs. The major advantage of the encyclopedia is manner in which it makes relevant information available not only to pathologists, but to all clinicians and researchers of the neighbouring disciplines working with pathologists who might wish to look up terms online. |
| anti her2 antibody therapy: Overcoming Cancers Resistant to HER-2 Antibodies Benjamin Bonavida, 2024-07-15 Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. - Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance - Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment - Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field |
| anti her2 antibody therapy: Management of Early Stage Breast Cancer Beena Kunheri, D. K. Vijaykumar, 2020-10-01 Breast cancer, its causes, early detection and treatment have received considerable attention, since this widespread disease is one of the most important health concerns for women. This book provides a comprehensive overview of the diagnostic and therapeutic aspects of the management of early-stage breast cancer, including essential information on basic topics like pathology, and radiology, as well as the latest developments. Further, it discusses all aspects of surgical care, chemotherapy and radiation therapy, together with the controversies and current management guidelines. Helping readers acquire a deep, holistic understanding of the topic, the book is a valuable resource for practitioners and postgraduate students in the field of gynecologic oncology. Moreover, it is a useful aid to decision-making in day-to-day practice for oncologists, residents, fellows and experienced practitioners. |
| anti her2 antibody therapy: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| anti her2 antibody therapy: The Breast K. I. Bland, Edward M. Copeland, 2009 Offering the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast, this surgical reference is now in a new edition available in both print and online for easy, convenient access to the absolute latest advances. |
| anti her2 antibody therapy: Single Domain Antibodies Dirk Saerens, Serge Muyldermans, 2012-08-10 The development of the hybridoma technology created the possibility to obtain unlimited amounts of monoclonal antibodies (mAb) with high specificity and affinity for any target and to introduce mAbs in a wide range of applications; however, the bulky size of mAbs, costly production, and cumbersome engineering hampered regularly their streamlined development in some applications. In Single Domain Antibodies: Methods and Protocols, expert researchers examine single variable domain antibody fragments, referred to as VH, VL, VHH or VNAR. These fragments are the smallest intact antigen-binding fragments that can be produced recombinantly at low cost. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. |
| anti her2 antibody therapy: Chimiothérapie Néo-adjuvante Claude Jacquillat, Marise Weil, David Khayat, 1988 |
| anti her2 antibody therapy: WHO Classification of Tumours of the Breast Sunil R. Lakhani, International Agency for Research on Cancer, 2012 WHO Classification of Tumours of the Breast is the fourth volume of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 90 authors from 24 countries, contains more than 340 colour photographs, tables and figures, and more than 1600 references. |
| anti her2 antibody therapy: HER2 Yosef Yarden, 2000 This book exemplifies the evolution of oncogene HER2-encoded enzyme from its discovery to the stage of a fully recognized target for breast cancer therapy. Intensive research over the last three decades has uncovered major mechanisms that regulate the transformation of a normal tissue to a malignant tumor. However, to the disappointment of many molecular biologists, these significant advances in identifying oncogenes, tumor-suppressors and critical signalling pathways have generated only limited impact in clinical oncology. This frustration may not persist for long: tailor-made drugs developed specifically to recognize molecular targets, and intercept biochemical engines whose intricacy is well understood, are on the verge of revolutionizing contemporary medicine. |
| anti her2 antibody therapy: Is the Recent Burst of Therapeutic Anti-Tumor Antibodies the Tip of an Iceberg? Leonor Kremer, Jose A. Garcia-Sanz, 2018-03-27 The high effectiveness of antibodies as anti-tumor therapeutic agents has led to a burst of research aiming to increase their therapeutic applications by the use of antibodies against new targets, new antibody formats or new combinations. In this e-book we present relevant research depicting the current efforts in the field. |
| anti her2 antibody therapy: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. |
| anti her2 antibody therapy: Antibody-Mediated Drug Delivery Systems Yashwant V. Pathak, Simon Benita, 2012-04-17 This book covers various aspects of antibody mediated drug delivery systems – theoretical aspects, processing, viral and non-viral vectors, and fields where these systems find and /or are being evaluated for applications as therapeutics and diagnostic treatment. Chapters discuss actual applications of techniques used for formulation and characterization. Applications areas include cancer, pulmonary, ocular diseases; brain drug delivery; and vaccine delivery. The contributing authors represent over 10 different countries, covering recent developments happening around the globe. |
| anti her2 antibody therapy: Therapeutic Monoclonal Antibodies Zhiqiang An, 2011-09-20 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories. |
| anti her2 antibody therapy: Recombinant Antibodies for Cancer Therapy Martin Welschof, Jürgen Krauss, 2008-02-05 Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients. |
| anti her2 antibody therapy: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors Jessica Dal Col, Alejandro López-Soto, Riccardo Dolcetti, 2020-06-04 |
| anti her2 antibody therapy: Monoclonal Antibodies—Advances in Research and Application: 2012 Edition , 2012-12-26 Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| anti her2 antibody therapy: Antibody-Drug Conjugates Kenneth J. Olivier, Jr., Sara A. Hurvitz, 2016-11-14 Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development |
Download Free Antivirus for Windows 10 PCs & Laptops | Avast
I had recommended Avast™ to a co-working friend because he said his computer was running slow. He said he ran the anti-virus twice and his computer speed improved.
Download Free Antivirus Software | Avast 2025 PC Protection
While it’ll keep your computer relatively safe against most types of malware, its anti-phishing protection is limited to Microsoft Edge — so you’ll need Avast Free Antivirus to protect you on …
Download Free Antivirus Software for Windows 11 | Avast
Strengthen your Windows 11 PC security and protect your entire home Wi-Fi network, plus get advanced tools like anti-malware security, Wi-Fi security scans, and more — all completely free.
Avast | Download Free Antivirus & VPN | 100% Free & Easy
Join 435 million others and get award-winning free antivirus for PC, Mac & Android. Surf safely & privately with our VPN. Download Avast today!
Avast | Download Free Antivirus & VPN | 100% Free & Easy
Join hundreds of millions of others & get free antivirus for PC, Mac, & Android. Surf safely with our VPN. Download Avast!
Télécharger antivirus gratuit | Protection Avast 2025 pour PC
Agent anti-ransomwares Protégez mieux vos informations personnelles. Ne laissez pas vos documents personnels (photos, fichiers…) devenir l’otage d’un ransomware.
Anti-Tracking Software | Download Avast AntiTrack
Anti-tracking software alone doesn’t protect you against malware and viruses. It’s designed to help block advertisers and trackers from collecting and sharing your data. In addition, anti …
The Best Free Antivirus Software for Windows in 2025 - Avast
Feb 2, 2022 · Core protection capabilities: While PCMag highlights Windows Defender’s strong performance in anti-malware tests, they found the program’s anti-phishing protections lacking. …
Avast Offline Installation Files | Avast
For small businesses and home office we recommend using our Avast Business Security and Antivirus installation file, for unmanaged solutions. For managed solutions, please use the …
Free Virus Scanner | Virus Scan & Removal Software - Avast
Windows Defender lacks many essential features that other free antivirus security solutions provide, such as offline protection and comprehensive anti-phishing defenses. Instead of …
Combining trastuzumab (Herceptin®) with hormonal therapy …
Hormonal therapy and the humanised anti-HER2 monoclonal antibody trastuzumab (Herceptin ®) represent one of the oldest and one of the newest treatment modalities for breast cancer, …
Development of paclitaxel-loaded liposomal systems with …
anti-her2 antibody for targeted therapy Gülay Büyükköroğlu1, Behiye Şenel1, Ebru Başaran2 and Seval Gezgin3 1Department of Pharmaceutical Biotechnology, 2Department of …
Ex vivo dual gene therapy using human adipocytes secreting …
Anti-tumor ecacy was evaluated in HER2-positive-cancer-inoculated nude mice. Results Anti-HER2 antibody against domain II was identied in supernatants from PER-ccdPAs. The optimal …
HER2-Positive Metastatic Breast Cancer: A Comprehensive …
therapy with anti-HER2 therapy has been widely adopted in the metastatic setting. Pertuzumab (Perjeta, Genentech), a second-genera-tion anti-HER2 antibody, binds to subdomain II of the …
Zanidatamab, an anti-HER2 bispecific antibody, plus …
chemotherapy plus tislelizumabin patients with HER2-positive unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma. Conclusions. Poster No. …
ENGINEERING ANTI-HER2 ANTIBODIES FOR ENHANCED
Antibody therapy, such as the anti-HER2 antibody trastuzumab, is used in the clinical setting to treat these cancers. Unfortunately, these cancers can resist trastuzumab treatment through …
Antibody-drug Conjugates: A Novel Paradigm for Cancer …
Anti-HER2 Antibody Conc. (ng/mL) Abs.(OD450nm-Blank) Human HER2/ERBB2 Protein Cat#: 10004-H27H2-B Immobilized human CD22 can bind anti-human CD22 Mab ... An insight into …
Therapeutic potential of an anti-HER2 single chain …
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer ... To develop a more effective therapy for human epidermal growth …
Comparison of the Efficacy, Safety, Pharmacokinetic and …
,7 This anti-HER2 monoclonal antibody was associated with a significantly longer time to disease progression, higher response rate, longer response duration, and improved OS. 4 Despite the …
SHR-A1811 (antibody-drug conjugate) in advanced HER2 …
months.17–22 However, anti-HER2 mAb monotherapy had consis-tently demonstrated limited antitumor activity for HER2-altered NSCLC.23,24 Recently, the advent of antibody-drug …
Zanidatamab, a HER2-targeted bispecific antibody, in …
deaths.1 Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 15–25% of gastric cancers.2 Zanidatamab (ZW25) is a novel HER2-targeted bispecific antibody. …
Efficacy and safety of KN026, a bispecific anti-HER2 …
ARTICLE OPEN Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast
224036_FG_VENTANA®_HER2_assay_Folder_250gr.indd
observed with the anti-HER2 treatment trastuzumab deruxtecan in breast cancer patients with low levels of HER2 expression.23,23 Trastuzumab deruxtecan is an antibody-drug conjugate that …
Targeting HER2+ Tumors
In vitro, the expression of anti-HER2 antibody is induced in response to a small molecule inducer in a dose dependent manner. Likewise, in vivo (using AAV-mediated transgene delivery), anti …
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New …
it has an enormous impact on the therapy selection. At present, HER2 expression is assessed using tissue biopsies. However, even with such patient selection, treatment failure still occurs, …
Clinical best practices in interdisciplinary management of …
of ILD/p in patients treated with anti‐HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p …
Dose escalation and pharmacokinetic study of a humanized …
humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer Y Tokuda 1 , T Watanabe 2 , Y Omuro , M Ando , N Katsumata 2 , A Okumura 1 …
Phase I trial of 131I GMIB Anti HER2 VHH1, a candidate for …
Dec 4, 2020 · Running title: 131I‐GMIB‐Anti‐HER2‐VHH1 in HER2‐therapy ... tyrosine kinase inhibitors (lapatinib) that interact with the intracellular domain of HER2, or antibody‐drug …
Synergistic antitumor activity between HER2 antibody-drug …
ARTICLE OPEN Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer Hongfu Liu 1,2,4, Dongdong Zhou2,3,4, …
Novel Conditionally Active Bispecific HER2 x CD3 T-Cell
RATIONALE RESULTS RESULTS Novel Conditionally Active Bispecific HER2 x CD3 T-Cell Engager Targeting Solid Tumors Ana Paula Cugnetti, Haizhen Liu, Patricia McNeely, Christina …
In vitro and in vivo evaluation of anti-HER2 antibody …
Keywords: HER2, Pertuzumab, Trastuzumab, Actinium-225, Targeted alpha therapy, SKOV-3, MDA-MB-231 Background e human epidermal growth factor receptor type 2 (HER2) is a …
Targeting cancer with antibody-drug conjugates: Promises …
retained in the parent mAb that inhibits HER2-signaling.14 Despite such anti-tumor activity, resistance to T-DM1 remains a challenge and will be discussed further in later sections.15 To …
Clinical best practices in interdisciplinary management of …
of ILD/p in patients treated with anti‐HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p …
Cancer Cell Article - Cell Press
Although anti-HER2/neu antibody is an effective adjuvant therapy targeting HER2+ breast cancers, relapse often occurs even after prolonged treatment. Current understanding holds …
IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in …
IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study. Subject JCO 2025.43:1029 …
A phase I trial of the trifunctional anti Her2 × anti CD3 …
when treated i.p. with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab [15]. Recently, Kiewe et al. published promising data for the trifunctional anti-Her2/neu x anti-CD3 …
Technical Data Sheet
HER2 overexpression is associated with poorer overall survival rates, shorter times to disease progression, and increased resistance to chemotherapy. Because of these clinical …
Exploring DESTINY: the Past, Present, and Future of
G1 monoclonal antibody targeting HER2 followed by a cleavable peptide linker bound to a derivative of DX-8951 (DXd), a potent topoisomerase I inhibitor payload [1–3]. Lysosomal …
A Biparatopic HER2-Targeting Antibody-Drug Conjugate ...
Jan 11, 2016 · to be an effective therapy for treating HER2-positive metastatic breast cancer. To date, three HER2-specific monoclonal anti-bodies have been approved by regulatory …
Establishment of a Novel Cancer-Specific Anti-HER2 …
Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H 2Mab-250/H 2CasMab-2 for Breast Cancers Mika K. Kaneko, Hiroyuki Suzuki, and Yukinari Kato ... in …
Anti‐HER2 Drugs for the Treatment of Advanced HER2
Trastuzumab is a humanized monoclonal antibody that binds selectively to HER2 receptor, inhibiting the proliferation of cells that overexpress HER2. ... which received 3rd line therapy …
Validation of the 4B5 rabbit monoclonal antibody in …
the humanized anti-Her2/neu monoclonal antibody therapy trastuzumab and chemotherapy.2–5 Trastuzumab therapy, however is associated with cardiotoxicity, in 2–4.7% of patients when used
Annals of Oncology abstracts
Background: BL-M07D1 is an anti-HER2 antibody drug conjugate (ADC). It consists of a humanized anti-HER2 antibody, a cathepsin B cleavable linker, and a novel topo-isomerase I …
Immuno-hyperthermia effected by antibody-conjugated …
Hyperthermia has been used for cancer therapy for a long period of time, but has shown limited clinical efficacy. Induction-heating hyperthermia using the combination of magnetic …
KN026 (anti-HER2 bispecific antibody) in patients with …
Anti-HER2 therapy was introduced in the treatment armamen-tarium of GC/GEJC in 2010. In combination with chemotherapy, Trastuzumab, an anti-HER2 antibody, ... KN026 is a …
Engineering an anti-HER2 biparatopic antibody with a …
ARTICLE Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action Florian Kast 1, Martin Schwill 1,6, Jakob C. Stüber 1,7, Svende Pfundstein1,2, Gabriela Nagy …
Evaluation of an 131I-labeled HER2-specific single domain …
of anti-HER2 sdAb 5F79, which binds to the same HER2 Domain IV epitope as ado-trastuzumab emtansine 21, as a delivery vehicle for the development of HER2 RPT agents. As expected, a …
125409Orig1s051 - Food and Drug Administration
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein …
Establishment of a Novel Cancer-Specific Anti-HER2 …
important target for monoclonal antibody (mAb) therapy. All therapeutic mAbs, including anti-HER2 mAbs, exhibit adverse effects probably due to the recognition of antigens expressed in …
Recent advances of antibody-drug conjugates in treating …
in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic …
Trastuzumab Emtansine: A Review of Its Use in Patients with …
antibody-drug conjugates that use antibodies to deliver cytotoxic therapy directly to cancer cells, thereby mini-mizing exposure to normal tissue [3, 4]. Trastuzumab emtansine (KadcylaTM) is …
Efficacy and safety of recombinant humanized anti-HER2 …
tively good prognosis. Whether antibody-drug conjugates (ADCs) can replace traditional che-motherapy combined with dual-target therapy in neoadjuvant therapy still needs to be …
Development of ABX-EGF, a fully human anti-EGF receptor …
to allow repeated administration without human anti-human antibody response. This provides a significant advantage in antibody therapy of chronic and recurring human disease, such as …
Research advancements of antibody drug conjugates in non …
breast and gastric cancers. Anti-HER2 targeted therapy, when combined with chemotherapy, has demonstrated markedly superior outcomes compared to chemother-apy alone in advanced …
Unlocking the Potential: Biomarkers of Response to Antibody …
Jun 3, 2024 · patients with HER2-negative (IHC 0) metastatic BC al-though tumors expressing higher HER2 levels had a better clinical response.9 HER2 overexpression actionability has …
Annals of Oncology abstracts
Background: BL-M07D1 is an anti-HER2 antibody drug conjugate (ADC). It consists of a humanized anti-HER2 antibody, a cathepsin B cleavable linker, and a novel topo-isomerase I …
Current and future landscape of targeted therapy in HER2 …
trial.26–29 Dual targeted bi-specific HER2 anti-bodies are also in development, including those targeting multiple HER2 epitopes, anti-HER2/ CD3, and anti-HER2/human epidermal growth …
Evaluation of the safety, pharmacokinetics, and efficacy of …
Background: JSKN003 is a bispecific HER2-directed antibody-drug conjugate (ADC) conju- ... 45.6% of pts received prior anti-HER2 and anti-HER2 ADC therapy, respectively. The median …
A new anti-HER2 antibody that enhances the anti-tumor …
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action Xuesai Zhang1, Jianhe Chen1, ... zumab based therapy. …
Efficacy and safety of HER2-ADC SHR-A1811 in HER2 …
Systemic HER2-target therapy is a viable option for these patients. The new generation of HER2-directed antibody-drug conjugate (ADCs) has signif-icantly altered the treatment landscape for …
